Investigation of the efficacy and safety of a diindolylmethane-based drug in patients with cervical intraepithelial neoplasia grades 1-2 (CIN 1-2)

Objective. To investigate the efficacy and safety of the vaginal suppositories Cervicon-DIM (diindolylmethane) in patients with histologically confirmed neoplastic processes of the cervix uteri - cervical intraepithelial neoplasia grades 1-2 (CIN 1-2). Subject and methods. The randomized study enrolled 160 patients aged 18 to 45 years; the follow-up period was 3 months. The investigators analyzed clinical and laboratory data and evaluated the efficacy and safety of treatment with Cervicon-DIM versus placebo. Results. Cervicon-DIM was shown to contribute to the elimination of human papillomavirus infection and to the regression of mild and moderate neoplastic processes of the cervix uteri (CIN 1-2). Conclusion. It is appropriate to prescribe Cervicon-DIM as one suppository (100 mg) twice daily for 3 months to patients with human papillomavirus infection and those with CIN 1-2. © 2018, Bionika Media Ltd. All rights reserved.